Breakthroughs in Immune Checkpoint Therapy: Overcoming Resistance with Novel Techniques

920
Total views and downloads

Participate in this topic

Articles

ORIGINAL RESEARCH

Accepted on 25 Mar 2025

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono-and combination immune checkpoint blockade

Przemysław Bielski
Jan Barczyński
Michał Mikitiuk
Maja Myrcha
Urszula Tyrcha
Aleksandra Hec-Gałązka
Tad A. Holak
Tomasz Sitar

doi 10.3389/fimmu.2025.1486799

224 views

Share on

Frontiers in Immunology

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.5 impact factor
- 6.2 citescore

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

920Topic views
224Article views